The company will not receive any proceeds from the resale or other disposition of the shares of common stock by the selling securityholders.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCAB:
- BioAtla reports Q1 EPS (26c), consensus (29c)
- BioAtla announces poster presentations at 2025 AACR meeting
- BioAtla price target lowered to $1 from $5 at Citizens JMP
- BioAtla’s Earnings Call: Clinical Progress and Strategic Outlook
- Positive Outlook for BioAtla: Strategic Moves and Promising Developments Signal Potential Upside